Because the EGFR mutation is one of the most frequent driver mutations in NSCLC, and as driver mutations in NSCLCs are usually present in mutually exclusive fashion, performing the Idylla EGFR Mutation Test prior to a multiplex genetic test may be a reasonable strategy to reduce the medical expenses of molecular profiling for NSCLC patients (Figure 3B). This evidence concerns the gene EGFR and non-small cell lung carcinoma.